Spinal cord stimulation alleviates cognitive deficits in chronic pain by targeting the microglial lnc-PCM1/PKC/IFN-γ axis to resolve neuroinflammation

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Neuroinflammation plays a pivotal role in chronic pain with cognitive dysfunction (CPCD), a debilitating condition where effective treatments are limited. While spinal cord stimulation (SCS) is an established analgesic therapy, its potential to ameliorate cognitive deficits via central immunomodulation remains largely unexplored. Methods: A rat model of CPCD was established by spared nerve injury (SNI). We employed RNA sequencing to identify SCS-regulated long non-coding RNAs (lncRNAs) in the prefrontal cortex (PFC). The functional role of a specific microglial lncRNA, lnc-PCM1, was investigated using adeno-associated virus (AAV)-mediated approaches, behavioral tests, molecular assays, and primary cell co-cultures. Results: SCS treatment significantly improved cognitive function in CPCD rats. We identified lnc-PCM1 as a key mediator, predominantly expressed in microglia, whose expression was suppressed by SCS. Mechanistically, SCS-mediated inhibition of lnc-PCM1 upregulated its target PCM1, thereby attenuating the protein kinase C (PKC) phosphorylation / interferon-gamma (IFN-γ) signaling axis. This led to a reduction in microglial M1 polarization and pro-inflammatory cytokine release. Consequently, SCS mitigated IFN-γ-driven neuronal oxidative stress, apoptosis, and synaptic damage in the PFC. Critically, the therapeutic benefits of SCS on cognition and neuroinflammation were abolished by overexpressing lnc-PCM1 or knocking down PCM1. Conclusions: Our study unveils a novel immunomodulatory mechanism of SCS: it ameliorates CPCD by resolving neuroinflammation through targeting the microglial lnc-PCM1/PKC/IFN-γ pathway. These findings position lnc-PCM1 as a promising new target for immunopharmacological interventions in chronic pain-related cognitive disorders. This cascade not only inhibited microglial pro-inflammatory activation but also restored PFC neuronal synaptic integrity, which collectively contributed to cognitive rescue.

Article activity feed